<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Stormo AED</submitter><funding>NIA NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>Laurel Endowment</funding><funding>Fondo di Ateneo per la Ricerca</funding><funding>UCSF Parnassus Flow Cytometry Core</funding><funding>National Institutes of Health</funding><funding>Fondazione Banco di Sardegna</funding><funding>Stowers Family Endowed Chair for Dental &amp;amp; Mineralized Tissue Research</funding><funding>NEI NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>DoD</funding><funding>NINDS NIH HHS</funding><funding>NCI NIH HHS</funding><funding>American Federation for Aging Research</funding><funding>DRC Center</funding><funding>Taube Koret Center</funding><funding>Michael J Fox Foundation</funding><funding>NIH HHS</funding><pagination>e202010065</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8919618</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>221(4)</volume><pubmed_abstract>Missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD); however, pathways regulating LRRK2 subcellular localization, function, and turnover are not fully defined. We performed quantitative mass spectrometry-based interactome studies to identify 48 novel LRRK2 interactors, including the microtubule-associated E3 ubiquitin ligase TRIM1 (tripartite motif family 1). TRIM1 recruits LRRK2 to the microtubule cytoskeleton for ubiquitination and proteasomal degradation by binding LRRK2911-919, a nine amino acid segment within a flexible interdomain region (LRRK2853-981), which we designate the "regulatory loop" (RL). Phosphorylation of LRRK2 Ser910/Ser935 within LRRK2 RL influences LRRK2's association with cytoplasmic 14-3-3 versus </pubmed_abstract><journal>The Journal of cell biology</journal><pubmed_title>The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.</pubmed_title><pmcid>PMC8919618</pmcid><funding_grant_id>SCR_018206</funding_grant_id><funding_grant_id>R01 EY027810</funding_grant_id><funding_grant_id>P30 DK063720</funding_grant_id><funding_grant_id>R01 CA219815</funding_grant_id><funding_grant_id>K08NS090633</funding_grant_id><funding_grant_id>R01 NS107480</funding_grant_id><funding_grant_id>S10 RR026758</funding_grant_id><funding_grant_id>R01 NS124848</funding_grant_id><funding_grant_id>RF1 AG058476</funding_grant_id><funding_grant_id>K08 NS090633</funding_grant_id><funding_grant_id>2014.0489</funding_grant_id><funding_grant_id>R01CA219815</funding_grant_id><funding_grant_id>RF1 NS124848</funding_grant_id><funding_grant_id>P01 AG054407</funding_grant_id><funding_grant_id>R01EY027810</funding_grant_id><funding_grant_id>W81XWH-18-1-0376</funding_grant_id><funding_grant_id>NIG P30 DK063720</funding_grant_id><pubmed_authors>Earley EM</pubmed_authors><pubmed_authors>Cox TC</pubmed_authors><pubmed_authors>Skibinski G</pubmed_authors><pubmed_authors>van Haren J</pubmed_authors><pubmed_authors>Von Dollen J</pubmed_authors><pubmed_authors>FitzGibbon M</pubmed_authors><pubmed_authors>Dauer WT</pubmed_authors><pubmed_authors>Lum LS</pubmed_authors><pubmed_authors>Finkbeiner S</pubmed_authors><pubmed_authors>Hiniker A</pubmed_authors><pubmed_authors>Wittmann T</pubmed_authors><pubmed_authors>Crosio C</pubmed_authors><pubmed_authors>Ahrendt H</pubmed_authors><pubmed_authors>Johnson JR</pubmed_authors><pubmed_authors>Stormo AED</pubmed_authors><pubmed_authors>Shavarebi F</pubmed_authors><pubmed_authors>Krogan NJ</pubmed_authors><pubmed_authors>Davis EJ</pubmed_authors><pubmed_authors>Mirescu C</pubmed_authors><pubmed_authors>Porath J</pubmed_authors><pubmed_authors>Verschueren E</pubmed_authors><pubmed_authors>Iaccarino C</pubmed_authors><pubmed_authors>Oakes SA</pubmed_authors><pubmed_authors>Swaney DL</pubmed_authors><pubmed_authors>Ravisankar A</pubmed_authors><pubmed_authors>Balen C</pubmed_authors><pubmed_authors>Nichols RJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.</name><description>Missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD); however, pathways regulating LRRK2 subcellular localization, function, and turnover are not fully defined. We performed quantitative mass spectrometry-based interactome studies to identify 48 novel LRRK2 interactors, including the microtubule-associated E3 ubiquitin ligase TRIM1 (tripartite motif family 1). TRIM1 recruits LRRK2 to the microtubule cytoskeleton for ubiquitination and proteasomal degradation by binding LRRK2911-919, a nine amino acid segment within a flexible interdomain region (LRRK2853-981), which we designate the "regulatory loop" (RL). Phosphorylation of LRRK2 Ser910/Ser935 within LRRK2 RL influences LRRK2's association with cytoplasmic 14-3-3 versus </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-05-31T05:00:55.991Z</modification><creation>2025-02-19T01:53:42.02Z</creation></dates><accession>S-EPMC8919618</accession><cross_references><pubmed>35266954</pubmed><doi>10.1083/jcb.202010065</doi></cross_references></HashMap>